" class="no-js "lang="en-US"> Hill Ferguson - Medtech Alert
Tuesday, October 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Hill Ferguson

Hill Ferguson

About Hill Ferguson

Working to improve the health care system through 1) a relentless focus on the patient experience; 2) a strong desire to improve the lives of physicians; and 3) partnerships with employers and health plans which lower costs and improve quality and NPS.

Related Story

Industry News

 Grand Rounds and Doctor On Demand to Merge

Grand Rounds and Doctor On Demand to Merge, Creating First of its Kind Patient-Centric Integrated Virtual Healthcare Company

May 11 2021

Grand Rounds, a leader in healthcare quality and navigation, and Doctor On Demand, the nation’s […]